首页期刊介绍编委会投稿指南期刊订阅广告合作留言板联系我们English
李惠,郭文文,王荟荟,秦靖,张彩勤,赵菊梅,师长宏.抗 PD-1 单抗联合顺铂的新辅助治疗策略对 NSCLC 人源化小鼠模型肿瘤复发与转移的影响[J].中国实验动物学报,2022,30(6):751~758.
抗 PD-1 单抗联合顺铂的新辅助治疗策略对 NSCLC 人源化小鼠模型肿瘤复发与转移的影响
Neoadjuvant treatment strategy by anti-PD-1 immunotherapy combined with cisplatin inhibits recurrence and metastasis of NSCLC in a humanized mouse model
投稿时间:2022-03-23  
DOI:10. 3969 / j.issn.1005-4847. 2022. 06. 003
中文关键词:  人源化小鼠模型  非小细胞肺癌  新辅助治疗  帕博利珠单抗  顺铂
英文关键词:humanized mouse model  non-small cell lung cancer  neoadjuvant therapy  pembrolizumab  cisplatin
基金项目:
作者单位
李惠 1. 延安大学基础医学院,陕西 延安 716000
2. 空军军医大学实验动物中心,西安 710032 
郭文文 空军军医大学实验动物中心,西安 710032 
王荟荟 2. 空军军医大学实验动物中心,西安 710032
3. 甘肃中医药大学 基础医学院,兰州 730030 
秦靖 空军军医大学实验动物中心,西安 710032 
张彩勤 空军军医大学实验动物中心,西安 710032 
赵菊梅 延安大学基础医学院,陕西 延安 716000 
师长宏 空军军医大学实验动物中心,西安 710032 
Author NameAffiliation
LI Hui 1.Medical College of Yan’an University, Yan’an 716000, China. 2. Laboratory Animal Center, the Air Force Medical University, Xi’an 710032. 
GUO Wenwen Laboratory Animal Center, the Air Force Medical University, Xi’an 710032 
WANG Huihui 2.Laboratory Animal Center, the Air Force Medical University, Xi’an 710032. 3. School of Basic Medicine, Gansu University of Chinese Medicine, Lanzhou 730030 
QIN Jing Laboratory Animal Center, the Air Force Medical University, Xi’an 710032 
ZHANG Caiqin Laboratory Animal Center, the Air Force Medical University, Xi’an 710032 
ZHAO Jumei Medical College of Yan’an University, Yan’an 716000, China 
SHI Changhong Laboratory Animal Center, the Air Force Medical University, Xi’an 710032 
摘要点击次数: 110
全文下载次数: 39
中文摘要:
       目的 利用人源化小鼠模型探讨抗 PD-1 单抗联合顺铂的新辅助治疗策略对人非小细胞肺癌( non- small-cell lung cancer,NSCLC)术后复发与转移的影响。 方法 选择重度联合免疫缺陷小鼠 NCG,通过序贯移植人外周血单个核细胞(peripheral blood mononuclear cell,PBMC)和人非小细胞肺癌细胞的方法,构建免疫系统-肿瘤双人源化 NSCLC 小鼠移植模型;评估不同新辅助治疗策略的疗效,包括顺铂治疗、抗 PD-1 单抗(帕博利珠单抗)治疗以及联合治疗;通过小动物活体成像观察各治疗组小鼠术后肿瘤复发与转移情况;通过免疫组化分析肿瘤组织中 Ki67 的表达,观察肿瘤细胞增殖情况;利用免疫荧光分析肿瘤免疫微环境的变化。 结果 成功构建了免疫系统-肿瘤双人源化 NSCLC 小鼠模型,重建小鼠外周血、各脏器以及肿瘤组织中均有人免疫细胞的浸润;活体成像结果显 示新辅助抗 PD-1 单抗治疗能抑制肿瘤的复发及转移,联合治疗组效果最为显著;免疫组化结果显示联合治疗组中小鼠肿瘤组织 Ki67 表达明显降低;免疫荧光结果表明帕博利珠单抗治疗可增加肿瘤组织中人 CD45+ 免疫细胞、 CD8+免疫细胞的浸润,联合治疗后 CD45+ 免疫细胞、CD8+ T 细胞的浸润更为明显;此外,颗粒酶 B( granzyme B, GzmB)在 CD8+T 细胞杀伤肿瘤中发挥重要作用,免疫组织化学染色结果显示帕博利珠单抗治疗可增加肿瘤组织中 granzyme B 的浸润,联合治疗后 granzyme B 阳性细胞的浸润更为明显。 结论 新辅助帕博利珠单抗联合顺铂有效提高了人源化小鼠免疫系统杀伤 NSCLC 的能力,显著抑制了 NSCLC 的复发和转移。
英文摘要:
       Objective To investigate the effect of a neoadjuvant treatment strategy of an anti-PD-1 monoclonal antibody combined with cisplatin on postoperative recurrence and metastasis of non-small cell lung cancer (NSCLC) in a humanized mouse model. Methods Human peripheral blood mononuclear cells and human NSCLC cells were sequentially transplanted into the severe combined immunodeficiency mouse (NOD/ ShiLtJGpt-Prkdcem26Cd52 Il2rgem26Cd22 / Gpt, NCG) to establish an immune system-tumor double humanized NSCLC model. We elevated the treatment effect of various neoadjuvant strategies in the double humanized NSCLC model, including cisplatin, anti-PD-1 ( pembrolizumab), and combined treatments. Tumor recurrence and metastasis were observed by optical imaging. Ki67 expression in tumor tissue was analyzed by immunohistochemistry to assess tumor cell proliferation. Changes in the tumor immune microenvironment were detected by immunofluorescence. Results The double humanized NSCLC model was successfully established. Immune cells had infiltrated into peripheral blood, organs, and tumors. Optical imaging showed that neoadjuvant anti-PD-1 treatment inhibited tumor recurrence and metastasis, and the effect of combined treatment was more obvious. Moreover, combination treatment significantly decreased Ki67 expression in tumor tissues. Large numbers of CD8+ and CD45+ cells in tumors were observed after anti-PD-1 treatment, and many more CD8+ and CD45+ T cells were found in the combined therapy group. Granzyme B plays an important role in tumor killing by CD8+ T cells. Immunohistochemical staining showed that anti-PD-1 treatment increased granzyme B in tumor tissues, which was more obvious after combined treatment. Conclusions Neoadjuvant pembrolizumab combined with cisplatin effectively improves the anti-tumor effect in humanized mice and significantly inhibits tumor recurrence and metastasis.
查看全文  查看/发表评论  下载PDF阅读器
关闭
您是第 3270030 位访问者
版权所有:中国实验动物学会 主管单位:中国科学技术协会 主办单位:中国实验动物学会    中国医学科学院医学实验动物研究所
地  址: 北京市朝阳区潘家园南里5号 邮编:100021 电话:010-67779337 E-mail:bjb2@cnilas.org
本系统由北京勤云科技发展有限公司设计
微信关注二维码